Ankaferd Blood Stopper Decreases Postoperative Bleeding and Number of Transfusions in Patients Treated with Clopidogrel: A Double-blind, Placebo-controlled, Randomized Clinical Trial

Creative Commons License

Akpinar M. B., Atalay A., Atalay H., Dogan O. F.

HEART SURGERY FORUM, cilt.18, sa.3, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1532/hsf.1256
  • Dergi Adı: HEART SURGERY FORUM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: The risk of reoperation due to bleeding after open heart surgery is 2.2%-4.2%. Extracorporeal circulation and emergency operations are the important risk factors. In coronary artery bypass graft (CABG) patients who are treated preoperatively with antiplatelets plus clopidogrel are the sources of postoperative bleeding. The aim of this study was to research the effect of local Ankaferd blood stopper (ABS) to prevent mediastinal bleeding in on-pump CABG patients who were treated with clopidogrel and acetylsalicylic acid (ASA) preoperatively.